Table 1.
Baseline patient characteristics.
| Characteristic | Total (n = 96) | PLC (n = 45) | MLC (n = 51) |
|---|---|---|---|
| Age (y) | 56.4 ± 12.8 | 57.0 ± 12.0 | 55.9 ± 13.5 |
| Sex | |||
| Male | 67 (69.8) | 36 (80.0) | 31 (60.8) |
| Female | 29 (30.2) | 9 (20.0) | 20 (39.2) |
| Tumor location | |||
| Unilobar | 41 (42.7) | 23 (51.1) | 18 (35.3) |
| Bilobar | 55 (57.3) | 22 (48.9) | 33 (64.7) |
| ECOG PS | |||
| 0 | 71 (74.0) | 39 (86.7) | 32 (62.7) |
| 1 | 25 (26.0) | 6 (13.3) | 19 (37.3) |
| Child-Pugh class | |||
| A | 92 (95.8) | 44 (97.8) | 48 (94.1) |
| B | 4 (4.2) | 1 (2.2) | 3 (5.9) |
| ALBI grade | |||
| 1 | 79 (82.3) | 35 (77.8) | 44 (86.3) |
| 2 | 17 (17.7) | 10 (22.2) | 7 (13.7) |
| Maximal tumor diameter | |||
| Mean ± SD (cm) | 4.2 ± 3.1 | 4.8 ± 3.8 | 3.7 ± 2.2 |
| < 5 cm | 68 (70.8) | 28 (62.2) | 40 (78.4) |
| ≥ 5 cm | 28 (29.2) | 17 (37.8) | 11 (21.6) |
| No. of tumors | |||
| ≤3 | 41 (42.7) | 29 (64.4) | 12 (23.5) |
| > 3 | 55 (57.3) | 16 (35.6) | 39 (76.5) |
| Vascular invasion | 12 (12.5) | 9 (20.0) | 3 (5.9) |
| Extrahepatic spread | 13 (13.5) | 6 (13.3) | 7 (13.7) |
| Chemotherapy agents | |||
| DHL alone | 32 (33.3) | 22 (48.9) | 10 (19.6) |
| Combined raltitrexed | 30 (31.3) | 13 (28.9) | 17 (33.3) |
| Combined irinotecan | 27 (28.1) | 7 (15.6) | 20 (39.2) |
| Combined oxaliplatin | 7 (7.3) | 3 (6.7) | 4 (7.8) |
Abbreviations: PLC, primary liver cancer; MLC, metastatic liver cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; ALBI, albumin-bilirubin; SD, standard deviation; DHL, doxorubicin hydrochloride liposome; MWA-TACE, microwave ablation combined with transarterial chemoembolization.